Provider review · Public documents checked September 27, 2026
NIOD CAIS3 review: why 1:1 does not mean 2% copper
Read the named components, current formula and testing summaries without converting them into a potency score.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
The NIOD name contains several clues that are easy to compress into the wrong conclusion: Copper Amino Isolate Serum 3 1:1. The current product description explains what the manufacturer means by its two components. Reading that explanation is more informative than adding the numbers or assuming a higher-generation name means a measured improvement over another formula.
Percentage, Please publishes within the CoreAge Rx promotional network. Our comparison gives CoreAge the first commercial placement, so that affiliation is relevant to this competing-product review. The work is an analysis of current NIOD records checked September 27, 2026, not an assay, a product-use diary, a clinician assessment or an independent reproduction of NIOD's testing.
In this article
The exact identity is CAIS3 serum
The product under review is Copper Amino Isolate Serum 3 1:1, also called CAIS3, which NIOD identifies as water-based. The page also displays Copper Amino Isolate Lipid, abbreviated CAIL, as a separate product. Similar names and shared promotional themes do not justify using one product's format, price or evidence to describe the other. Current CAIS3 page.
That identity should remain attached to every subsequent claim. A review of copper peptides generally would not establish which NIOD preparation a statement concerns. The source comparison follows the same approach across the three brands, rather than grouping every copper-related bottle under one interchangeable product category.
Read each component before doing any arithmetic
NIOD states that the serum contains 1% GHK-Cu and an additional 1% GHK. The first is its copper-peptide description; the second is separately identified GHK. Calling the result 2% copper would change what the manufacturer actually says. The 1:1 designation should stay tied to these named components rather than become a claim about elemental copper or a clinical strength score.
The current ingredient declaration uses Tripeptide-1 Copper Acetate and Tripeptide-1 Acetate among its listed ingredients. We have not independently measured either component. The grade-and-purity discussion explains why an attributed formulation statement and a verified analytical result are different kinds of evidence.
The serum contains more than those two descriptions
The disclosed list also includes water, glycerin, other peptides, Sodium Hyaluronate Crosspolymer, glycogen and additional formulation ingredients. That broader record matters because an outcome associated with use of the serum cannot automatically be assigned to one featured molecule. Nor can a complete response be predicted from the percentage in the name.
NIOD notes that its formulas can be updated and that the website list may differ from the box according to time and region of purchase. The relevant package can therefore be more specific than a remembered online ingredient list. FDA's cosmetic guide explains ingredient labeling but does not make it a complete quantitative recipe or a personal tolerance forecast. FDA labeling guide.
Testing summaries identify claims, but leave methods open
The page describes testing on 31 people for some four- and eight-week claims, and on 32 people for twelve-week claims. These are manufacturer summaries concerning the product's visible effects. The reviewed page does not include the full reports needed to inspect allocation, comparator conditions, measurement reliability or the distribution of individual results.
These counts cannot be assumed to represent independent studies whose participants may simply be pooled. The timing of an observed endpoint is also not a promise that each buyer will see the same change by that date. Our endpoint-reading guide distinguishes the report's measured question from the broader impression a marketing headline can create.
A different copper-peptide study cannot fill every gap
The older clinical abstract about GHK-Cu after laser resurfacing involved a specific postoperative setting around the mouth. It reported thirteen completers, no significant objective between-group improvement in the evaluated appearance outcomes and a favorable satisfaction finding. That evidence does not identify CAIS3 as the preparation used. Original study abstract.
It would therefore be misleading to add that trial to NIOD's small summaries and describe a single body of testing for this exact serum. The firmness-versus-results guide explains why satisfaction and measured facial changes should not be treated as interchangeable outcomes. The abstract's limited detail also leaves questions that this review cannot answer.
The size record belongs beside the price
The checked United States page showed $62 for the 15 mL option. A fresh read-only response from the site's public size selector identified $93 for the 30 mL option. The selector is useful evidence about those displayed variants; it is not proof of a completed order, shipping cost or future availability.
Neither amount should be assigned to the nearby CAIL product or converted into a monthly care cost without further information. We did not estimate application quantity or bottle duration. The monthly-price comparison keeps this type of retail quantity record distinct from a provider's plan advertised in months.
The comparison remains a question about evidence
NIOD supplies a relatively specific description of its two featured components, but specificity alone is not a clinical victory. The CoreAge evidence review examines a differently specified 2% offer, while the Ordinary review examines a multi-peptide serum named around 1%. None can be ranked by copying the printed numbers into a potency column.
A stronger comparison would require compatible specifications and relevant finished-product evidence with a clearly named outcome and comparator. Until that evidence is available, the defensible conclusion is about the record: what NIOD identifies, what its summaries describe and which questions remain unresolved.
Sources behind this reading
- NIOD Copper Amino Isolate Serum 3 1:1 product record ↗Manufacturer product page · Checked 2026-09-27
- FDA Cosmetics Labeling Guide ↗Regulator labeling guidance · Checked 2026-09-27
- Topical copper tripeptide complex after CO2 resurfacing: original study abstract ↗Primary clinical-study abstract · Checked 2026-09-27